Clinic
ST Elizabeth Medical Center, INC
ST Elizabeth Medical Center, INC was paid $45.99M by Medicaid between Jan 2018 and Dec 2024, across 268 billing codes. Its largest line is 99283, emergency room visit (moderate) — 16% of everything it billed.
33Billing provider infoST ELIZABETH MEDICAL CENTER, INC
FORT THOMAS, KY 41075
FORT THOMAS, KY 41075
33aNPI1740221795assigned 06/09/2006
33bProvider typeSubstance Use Disorder Rehabilitation Clinic/Center
28Total paid$45.99M
24GClaims696,134
24DCodes billed268
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Substance Use Disorder Rehabilitation Clinic/Center providers in Kentucky
Rank by total paid#2 of 28
Median peer was paid$2.73M
This provider vs. median17×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 117,869 | $6.11M | |
| 2019 | 110,102 | $6.42M | |
| 2020 | 77,818 | $4.89M | |
| 2021 | 88,206 | $5.46M | |
| 2022 | 94,872 | $6.34M | |
| 2023 | 117,897 | $9.92M | |
| 2024incomplete | 89,370 | $6.85M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 16% | 31,851 | 27,965 | $7.47M |
| 41899 | Unlisted procedure, dentoalveolar structures | 15% | 2,504 | 2,318 | $7.11M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 15% | 19,658 | 15,931 | $6.85M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 9.7% | 11,534 | 7,111 | $4.48M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 3.5% | 18,169 | 11,701 | $1.63M |
| G0378 | Hospital observation service, per hour | 3.2% | 7,725 | 2,984 | $1.47M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.1% | 6,889 | 6,177 | $1.45M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.6% | 8,028 | 7,489 | $1.21M |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 2.6% | 5,301 | 2,211 | $1.20M |
| J3490 | Unclassified drugs | 2.1% | 53,469 | 11,615 | $985K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.5% | 15,164 | 8,051 | $670K |
| 64493 | <1% | 415 | 281 | $453K |
256 more codes
| 71046 | Radiologic examination, chest; 2 views | <1% | 10,247 | $445K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 6,216 | $442K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 5,209 | $403K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 1,250 | $346K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 14,722 | $316K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 8,903 | $311K |
| 36415 | Collection of venous blood by venipuncture | <1% | 65,743 | $302K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 4,513 | $282K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 7,416 | $277K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 1,916 | $273K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 10,894 | $271K |
| 62323 | <1% | 580 | $266K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 4,070 | $254K |
| 64635 | <1% | 130 | $250K | |
| 71045 | Radiologic examination, chest; single view | <1% | 5,661 | $244K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 2,479 | $243K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 1,129 | $239K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 3,009 | $228K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 2,815 | $198K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 1,437 | $179K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 2,155 | $176K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 2,714 | $175K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 1,230 | $165K |
| 96376 | <1% | 4,792 | $163K | |
| 76830 | Ultrasound, transvaginal | <1% | 1,682 | $153K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 5,111 | $147K |
| 64494 | <1% | 303 | $144K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 353 | $136K |
| 66984 | Extracapsular cataract removal with insertion of intraocular lens prosthesis | <1% | 212 | $129K |
| 80053 | Comprehensive metabolic panel | <1% | 17,853 | $114K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 26,228 | $113K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 3,634 | $112K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 197 | $102K |
| 72100 | <1% | 2,113 | $95K | |
| 11043 | <1% | 306 | $94K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 547 | $88K |
| 73630 | <1% | 2,374 | $85K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 2,268 | $84K |
| 94726 | <1% | 543 | $83K | |
| 73564 | <1% | 1,919 | $79K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 1,619 | $78K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 18,482 | $78K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 286 | $76K |
| 10060 | <1% | 378 | $68K | |
| 71271 | <1% | 847 | $67K | |
| 73130 | <1% | 1,884 | $65K | |
| 84484 | <1% | 10,961 | $62K | |
| 73610 | <1% | 2,117 | $61K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 1,024 | $60K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 11,344 | $58K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 4,553 | $57K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 2,432 | $56K |
| 97162 | <1% | 1,162 | $51K | |
| 84702 | <1% | 7,363 | $50K | |
| 73030 | <1% | 1,584 | $48K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 1,291 | $46K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 937 | $46K |
| 80061 | Lipid panel | <1% | 4,189 | $44K |
| 12001 | <1% | 410 | $42K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 1,815 | $41K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 533 | $40K |
| 64636 | <1% | 64 | $40K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,836 | $40K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,820 | $40K |
| 96367 | <1% | 901 | $40K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 1,885 | $39K |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 31 | $39K |
| 73110 | <1% | 1,184 | $35K | |
| 29125 | <1% | 347 | $35K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 307 | $34K |
| 85027 | <1% | 9,630 | $34K | |
| 82962 | <1% | 8,788 | $33K | |
| 83690 | <1% | 8,552 | $30K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 8,624 | $30K |
| J0689 | Injection, cefazolin sodium (baxter), not therapeutically equivalent to j0690, 500 mg | <1% | 1,227 | $29K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 2,855 | $29K |
| 71250 | <1% | 451 | $29K | |
| 93971 | <1% | 339 | $25K | |
| 77066 | Tomosynthesis, mammo | <1% | 323 | $25K |
| 93017 | <1% | 235 | $25K | |
| 83880 | <1% | 1,375 | $23K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 1,101 | $22K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 984 | $22K |
| 82565 | <1% | 1,825 | $22K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 2,671 | $22K |
| 94729 | <1% | 374 | $21K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 727 | $20K |
| 80076 | <1% | 3,902 | $20K | |
| 90853 | Group psychotherapy (other than of a multiple-family group) | <1% | 926 | $19K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 2,337 | $19K |
| 76642 | <1% | 340 | $18K | |
| 87631 | <1% | 185 | $18K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 7,598 | $17K |
| 85610 | <1% | 6,996 | $17K | |
| 81025 | <1% | 1,149 | $17K | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 3,947 | $17K |
| 99219 | <1% | 316 | $17K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 16,051 | $16K |
| 82077 | <1% | 1,937 | $16K | |
| 81001 | <1% | 8,079 | $16K | |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | <1% | 632 | $16K |
| 70496 | <1% | 130 | $16K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 4,616 | $15K |
| 73502 | <1% | 481 | $15K | |
| 90715 | <1% | 834 | $14K | |
| 76770 | <1% | 193 | $14K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 3,415 | $14K |
| 85379 | <1% | 2,613 | $13K | |
| 70498 | <1% | 156 | $13K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 72 | $13K |
| 74018 | <1% | 306 | $13K | |
| 83605 | <1% | 2,312 | $13K | |
| G0297 | Low dose ct scan (ldct) for lung cancer screening | <1% | 173 | $13K |
| 36591 | <1% | 218 | $11K | |
| 82607 | <1% | 690 | $10K | |
| 84703 | <1% | 2,517 | $10K | |
| 76536 | <1% | 122 | $10K | |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 13 | $10K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 353 | $10K |
| 87522 | Neg quan hep c or qual rna | <1% | 273 | $10K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 6,829 | $9K |
| 77080 | <1% | 177 | $9K | |
| 86900 | <1% | 682 | $9K | |
| 73080 | <1% | 276 | $9K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 1,737 | $9K |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 793 | $9K |
| 87430 | <1% | 1,499 | $9K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 3,202 | $9K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 6,854 | $8K |
| 83735 | <1% | 2,169 | $8K | |
| 84145 | <1% | 566 | $8K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 536 | $8K |
| 84439 | <1% | 975 | $8K | |
| 71101 | <1% | 185 | $8K | |
| 81003 | <1% | 4,423 | $7K | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 36 | $7K |
| 72050 | <1% | 127 | $7K | |
| 87077 | <1% | 1,206 | $7K | |
| 82803 | <1% | 527 | $7K | |
| 88304 | <1% | 333 | $6K | |
| 86140 | <1% | 1,540 | $6K | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 3,005 | $6K |
| 12002 | <1% | 39 | $6K | |
| J1815 | Injection, insulin, per 5 units | <1% | 2,970 | $6K |
| 94761 | <1% | 434 | $5K | |
| 70491 | <1% | 42 | $5K | |
| 70486 | <1% | 72 | $5K | |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | <1% | 130 | $5K |
| C9290 | Injection, bupivacaine liposome, 1 mg | <1% | 48 | $5K |
| 97161 | <1% | 146 | $5K | |
| 87040 | <1% | 685 | $4K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 2,071 | $4K |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 408 | $4K |
| 87186 | <1% | 994 | $4K | |
| 80074 | <1% | 199 | $4K | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 1,037 | $3K |
| 82570 | <1% | 725 | $3K | |
| 94060 | <1% | 17 | $3K | |
| 76942 | <1% | 40 | $3K | |
| 82728 | <1% | 310 | $3K | |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | <1% | 249 | $3K |
| 85652 | <1% | 1,494 | $3K | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 1,414 | $3K |
| 82746 | <1% | 230 | $3K | |
| 80143 | <1% | 340 | $3K | |
| 73140 | <1% | 139 | $3K | |
| 87070 | <1% | 563 | $2K | |
| 93880 | <1% | 25 | $2K | |
| 29515 | <1% | 13 | $2K | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 118 | $2K |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 37 | $2K |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 1,107 | $2K |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 1,124 | $2K |
| 36416 | <1% | 211 | $2K | |
| V2632 | Posterior chamber intraocular lens | <1% | 58 | $2K |
| 87210 | <1% | 944 | $2K | |
| 93923 | <1% | 38 | $2K | |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 783 | $2K |
| 93970 | <1% | 12 | $2K | |
| 87205 | <1% | 787 | $2K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 26 | $2K |
| 95886 | <1% | 13 | $2K | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 1,331 | $2K |
| 80069 | <1% | 244 | $2K | |
| 85730 | <1% | 528 | $2K | |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 37 | $2K |
| 97010 | <1% | 206 | $2K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 1,878 | $2K |
| 80179 | <1% | 243 | $2K | |
| 88307 | <1% | 12 | $2K | |
| 86850 | <1% | 233 | $2K | |
| 73590 | <1% | 60 | $1K | |
| 73090 | <1% | 28 | $1K | |
| 83540 | <1% | 296 | $1K | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 2,359 | $1K |
| 88738 | <1% | 152 | $1K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 12 | $1K |
| 86901 | <1% | 675 | $1K | |
| Q9969 | Tc-99m from non-highly enriched uranium source, full cost recovery add-on, per study dose | <1% | 129 | $1K |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 895 | $1K |
| 86780 | <1% | 128 | $1K | |
| 93225 | <1% | 17 | $1K | |
| 94010 | <1% | 13 | $1K | |
| 83550 | <1% | 166 | $998.63 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 579 | $990.45 |
| 87340 | <1% | 110 | $949.96 | |
| 83970 | <1% | 24 | $885.04 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 144 | $880.03 |
| 77065 | Tomosynthesis, mammo | <1% | 15 | $877.80 |
| 86481 | <1% | 12 | $855.95 | |
| 96415 | <1% | 14 | $852.35 | |
| 72072 | <1% | 15 | $834.01 | |
| 97116 | <1% | 62 | $792.82 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 526 | $785.54 |
| 93226 | <1% | 15 | $745.47 | |
| 82550 | <1% | 176 | $671.51 | |
| J1980 | Injection, hyoscyamine sulfate, up to 0.25 mg | <1% | 53 | $571.51 |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 147 | $551.45 |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 585 | $519.84 |
| P9612 | Catheterization for collection of specimen, single patient, all places of service | <1% | 48 | $507.79 |
| 86803 | <1% | 41 | $492.74 | |
| 87808 | <1% | 46 | $479.16 | |
| 84100 | <1% | 138 | $447.17 | |
| J0697 | Injection, sterile cefuroxime sodium, per 750 mg | <1% | 122 | $441.48 |
| G0008 | Administration of influenza virus vaccine | <1% | 13 | $365.30 |
| 82805 | <1% | 47 | $326.64 | |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 74 | $297.70 |
| J0134 | Injection, acetaminophen (fresenius kabi), not therapeutically equivalent to j0131, 10 mg | <1% | 92 | $295.59 |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 16 | $275.00 |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 61 | $266.53 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 23 | $225.23 |
| 82043 | <1% | 38 | $183.79 | |
| A9270 | Non-covered item or service | <1% | 495 | $175.52 |
| 90686 | <1% | 18 | $169.32 | |
| 87807 | <1% | 67 | $158.08 | |
| 82977 | <1% | 128 | $153.22 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 69 | $132.04 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 100 | $130.72 |
| 87088 | <1% | 28 | $122.25 | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 64 | $62.23 |
| 84550 | <1% | 13 | $56.78 | |
| J1596 | Injection, glycopyrrolate, 0.1 mg | <1% | 136 | $50.95 |
| 99152 | <1% | 14 | $48.63 | |
| J3360 | Injection, diazepam, up to 5 mg | <1% | 15 | $45.71 |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 25 | $28.18 |
| J2470 | Injection, pantoprazole sodium, 40 mg | <1% | 25 | $25.33 |
| J1836 | Injection, metronidazole, 10 mg | <1% | 31 | $23.34 |
| Q0177 | Hydroxyzine pamoate, 25 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 697 | $17.52 |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 86 | $15.69 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 40 | $7.33 |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | <1% | 12 | $0.46 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 72 | $0.00 |
| J1580 | Injection, garamycin, gentamicin, up to 80 mg | 0% | 68 | $0.00 |
| 80305 | 0% | 13 | $0.00 | |
| 00142 | 0% | 107 | $0.00 | |
| Q0164 | Prochlorperazine maleate, 5 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | 0% | 35 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialRITCHEY-BALDWIN, LORI (CFO (INTERIM))
| Provider | Location | Paid |
|---|---|---|
| ST Elizabeth Medical Center, INC | Edgewood, KY | $188.25M |
| ST Elizabeth Medical Center, INC | Florence, KY | $65.44M |
| ST Elizabeth Medical Center, INC | Williamstown, KY | $35.42M |
| ST Elizabeth Medical Center, INC | Lawrenceburg, IN | $4.66M |
| ST Elizabeth Medical Center, INC | Erlanger, KY | $3.75M |
| ST Elizabeth Medical Center, INC | Edgewood, KY | $2.95M |
| ST. Elizabeth Medical Center, INC. | Edgewood, KY | $438.18 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.